Diproteverine HCl

CAS No. 69373-88-2

Diproteverine HCl( —— )

Catalog No. M36266 CAS No. 69373-88-2

Diproteverine HCl is a novel calcium antagonist with antianginal properties, antispasmodic and vasoactive.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 172 In Stock
10MG 254 In Stock
25MG 392 In Stock
50MG 551 In Stock
100MG 762 In Stock
200MG 1014 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Diproteverine HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Diproteverine HCl is a novel calcium antagonist with antianginal properties, antispasmodic and vasoactive.
  • Description
    Diproteverine HCl is a novel calcium antagonist with antianginal properties, antispasmodic and vasoactive.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Calcium Channel
  • Recptor
    Calcium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    69373-88-2
  • Formula Weight
    462.02
  • Molecular Formula
    C26H36ClNO4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.N1=C(C=2C=C(OC(C)C)C(OC(C)C)=CC2CC1)CC3=CC=C(OCC)C(OCC)=C3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Cronidipine

    Cronidipine (LF 20254), a calcium channel antagonist, is used potentially for the treatment of hypertension and myocardia ischemia.

  • Upacicalcet

    Upacicalcet (AJT-240) is an intraventricular calcium mimetic, a SHPT available for human hemodialysis, that inhibits excessive parathyroid hormone (PTH) secretion by directly acting on parathyroid cell membrane calcium-sensitive receptors, thereby lowering blood levels of PTH.

  • Zonisamide

    Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures.